700 drugs for women in pipeline, says PhRMA
The US Pharmaceutical Research and Manufacturers of America (PhRMA) has issued a report highlighting over 700 new drugs under development for diseases that disproportionately or only affect women. The study is titled: Medicines in Development for Women. Among the conditions targeted by drugmakers are: arthritis; women-specific cancers; diabetes; obstetric/gynecologic diseases; and mental illnesses.
Billy Tauzin, the PhRMA's president, speaking at an event to launch the study in Baton Rouge, Louisiana, said: "there is significant progress being made in the search for new cures and treatments for diseases of special concern to women." He added that "we are looking to a future where more women can lead long and healthy lives. These drugs that are now in development are helping us get there."
The drugs are broken down by therapeutic area, although some are included in several categories:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze